Literature DB >> 9246575

Steady-state effects of vitronectin and fibronectin on the binding, uptake, and degradation of Pneumocystis carinii in rat alveolar macrophages.

J S Hoyte1, J E Standing, A H Limper.   

Abstract

Pneumocystis carinii pneumonia remains a serious complication of immunodeficiency. Vitronectin (VN) and fibronectin (FN) accumulate in the lung during P. carinii infection and bind to the organism, thereby enhancing macrophage release of TNF alpha. It is not known whether VN and FN also regulate uptake and degradation of P. carinii by macrophage when present in concentrations similar to those in the lung during pneumonia. To address this, macrophages were cultured with 35S-radiolabeled P. carinii and organism binding, phagocytosis, and degradation determined in media alone (control), or in the presence of VN or FN (100 micrograms/ml each). Soluble VN and FN, in concentrations similar to those in the host, did not significantly affect binding uptake or degradation of P. carinii by alveolar macrophages. Thus, although VN and FN enhance macrophage activation during P. carinii pneumonia, phagocytosis of the organism is not increased by these host glycoproteins under steady-state conditions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9246575     DOI: 10.1023/a:1027354001187

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  31 in total

1.  Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS.

Authors:  A H Limper; K P Offord; T F Smith; W J Martin
Journal:  Am Rev Respir Dis       Date:  1989-11

2.  Role of fibronectin in Pneumocystis carinii attachment to cultured lung cells.

Authors:  S T Pottratz; W J Martin
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

3.  Exacerbation of murine Pneumocystis carinii infection by adenoviral-mediated gene transfer of a TNF inhibitor.

Authors:  J K Kolls; D Lei; C Vazquez; G Odom; W R Summer; S Nelson; J Shellito
Journal:  Am J Respir Cell Mol Biol       Date:  1997-02       Impact factor: 6.914

4.  Uptake and degradation of Pneumocystis carinii by macrophages in vitro.

Authors:  L A Von Behren; E L Pesanti
Journal:  Am Rev Respir Dis       Date:  1978-12

5.  The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung.

Authors:  A H Limper; J S Hoyte; J E Standing
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

6.  Mechanism of Pneumocystis carinii attachment to cultured rat alveolar macrophages.

Authors:  S T Pottratz; W J Martin
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

7.  A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes.

Authors:  J Shellito; V V Suzara; W Blumenfeld; J M Beck; H J Steger; T H Ermak
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

8.  Uptake of Pneumocystis carinii mediated by the macrophage mannose receptor.

Authors:  R A Ezekowitz; D J Williams; H Koziel; M Y Armstrong; A Warner; F F Richards; R M Rose
Journal:  Nature       Date:  1991-05-09       Impact factor: 49.962

9.  Surfactant protein D interacts with Pneumocystis carinii and mediates organism adherence to alveolar macrophages.

Authors:  D M O'Riordan; J E Standing; K Y Kwon; D Chang; E C Crouch; A H Limper
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

10.  The interaction in vitro of Pneumocystis carinii with macrophages and L-cells.

Authors:  H Masur; T C Jones
Journal:  J Exp Med       Date:  1978-01-01       Impact factor: 14.307

View more
  2 in total

Review 1.  Host cell invasion by medically important fungi.

Authors:  Donald C Sheppard; Scott G Filler
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-03       Impact factor: 6.915

Review 2.  Colonization by Pneumocystis jirovecii and its role in disease.

Authors:  Alison Morris; Karen A Norris
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.